Core Insights - The article highlights the rapid evolution of ultrasound diagnostic equipment towards intelligence and portability, with Xiangsheng Medical emerging as a representative enterprise in technological innovation and market expansion in the ultrasound AI field [1] Group 1: Technological Innovation - Xiangsheng Medical has positioned itself as a pioneer in the domestic ultrasound AI diagnostic sector, leveraging AI technology to enhance traditional ultrasound practices [2] - The company employs a dual-engine approach of "ultrasound artificial intelligence + specialized models" to drive innovation across various scenarios, establishing a comprehensive intelligent framework that covers device development, image acquisition, and diagnostic decision-making [2] - The company has achieved significant advancements in AI-assisted diagnostic technologies across multiple fields, including breast, liver, and cardiovascular diseases, with its breast ultrasound analysis software receiving medical device registration approval in 2022 [2] Group 2: Product Development and Applications - Xiangsheng Medical has launched the "Breast Artificial Intelligence Ultrasound Robot" system to address the challenges of mass screening for breast cancer in China, integrating ultrasound imaging, robotics, and AI technology into a comprehensive health management model [3] - The system features an original integrated design that includes a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, and AI-assisted diagnostic capabilities, facilitating large-scale efficient scanning and data tracking for breast cancer prevention and treatment [3] Group 3: Market Expansion and New Applications - The company is actively exploring new ultrasound application scenarios, achieving breakthroughs in areas such as helicopter medical rescue, precision aesthetic medicine, and veterinary ultrasound [4] - Xiangsheng Medical provided medical support at major sporting events, utilizing its self-developed 5G remote consultation system and portable ultrasound devices to enhance emergency response efficiency [4] - The company is expanding its portable intelligent product offerings in the aesthetic medicine sector and has entered various domestic and international medical institutions, including partnerships with notable organizations like the Gates Foundation for project funding [5]

Group 1 - The core viewpoint of the article highlights the performance of the Science and Technology Innovation Enhanced ETF (588520), which opened with a gain of 0.67% at 1.195 yuan [1] - The top holdings of the ETF include companies such as SMIC, which rose by 1.59%, and Cambricon, which increased by 3.76%, while others like Jianyuan Technology and Transsion Holdings experienced slight declines [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Composite Price Index, managed by Yongying Fund Management Company, with a return of 18.66% since its inception on June 27, 2025, and a return of 13.59% over the past month [1]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司"）股东无锡祥鼎 投资企业（有限合伙）（以下简称"祥鼎投资"）持有公司股份4,704,000股，占公司总股本的4.20%；股 东上海御德科技有限公司（以下简称"上海御德"）持有公司股份1,679,956股，占公司总股本的1.50%； 股东无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份1,344,000股，占公司总股本 的1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公司实施资本公积转增股本取 得的股份，涉及公司首次公开发行前取得的股份已于2022年12月3日解除限售并上市流通。 ● 减持计划的实施结果情况 ■ 上述减持主体存在一致行动人： ■ 二、减持计划的 ...

祥生医疗主营业务为医疗器械的研发、生产和销售，产品涵盖超声诊断设备及相关技术服务。公司2024 年年报显示，医疗器械业务收入占比达99.88%。 截至2025年8月21日收盘，祥生医疗股价报33.64元，较前一交易日下跌1.52%。当日成交额为0.42亿 元，换手率为1.09%。 公司8月21日晚间公告显示，股东祥鼎投资、上海御德、祥鹏投资的减持计划期限已届满，期间上述股 东未实施减持。根据公开数据，祥生医疗当日主力资金净流出319.18万元，近五日主力资金累计净流出 2339.86万元。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

（以下简称"祥鹏投资"）持有公司股份 1,344,000 证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙） （以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙） 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 ? 减持计划的实施结果情况 股份计划公告》，公司股东祥鼎投资拟自减持计划公告披露之日起 15 个 ...

Group 1 - The core point of the article is that Xiangsheng Medical (SH 688358) announced that its major shareholders did not reduce their holdings during the designated reduction period, which ends on August 21, 2025 [1] - As of the announcement, Xiangsheng Medical's market capitalization is 3.8 billion yuan [1] - For the fiscal year 2024, the revenue composition of Xiangsheng Medical is reported to be 99.88% from the medical device industry and 0.12% from other businesses [1]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 4 月 28 日，公司披露了《无锡祥生医疗科技股份有限公司股东减持 股份计划公告》， ...

Core Viewpoint - Xiangsheng Medical (688358.SH) announced that its shareholders, Xiangding Investment, Shanghai Yude, and Xiangpeng Investment, did not reduce their holdings during the designated reduction period, which ends on August 21, 2025 [1] Summary by Relevant Categories - Company Actions - The company received a notification letter regarding the reduction plan [1] - The reduction plan period has now expired without any shares being sold by the mentioned shareholders [1]

近日，祥生医疗（688358）发布股东减持计划时间届满暨减持股份结果公告。此前，股东祥鼎投资、上 海御德、祥鹏投资分别计划减持不超1.05%、0.37%、0.30%的公司股份。截至2025年8月21日减持期限 届满，三股东均未减持公司股份。减持前，祥鼎投资、上海御德、祥鹏投资分别持股4,704,000股、 1,679,956股、1,344,000股，占总股本比例分别为4.20%、1.50%、1.20%。本次实际减持情况与此前披露 的减持计划一致，且未提前终止减持计划。 ...

祥生医疗属于医疗器械行业，专注于超声医学影像设备的研发、生产和销售，产品涵盖全数字超声诊断 系统及相关技术服务。 截至2025年8月20日收盘，祥生医疗股价报34.16元，较前一交易日上涨0.24元，涨幅0.71%。当日成交 量为14824手，成交额0.50亿元，振幅2.18%。 来源：金融界 资金流向方面，8月20日主力资金净流出140万元，占流通市值的0.04%。近五个交易日累计净流出 2382.58万元，占流通市值的0.62%。 风险提示：股市有风险，投资需谨慎。 ...